Hester Biosciences Share Price
Sector: Biotechnology & Drugs
1868.00 +51.25 (2.82%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1776.60
Today’s High
1868.00
52 Week Low
1246.75
52 Week High
3375.45
1858.90 +37.60 (2.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1813.00
Today’s High
1860.00
52 Week Low
1242.95
52 Week High
3379.00
Key Metrics
- Market Cap (In Cr) 1589.69
- Beta 1.06
- Div. Yield (%) 0.38
- P/B 5
- TTM P/E 37.02
- Sector P/E 49.32
- D/E 0.01
- Open Price 1827.65
- Prev Close 1816.75
Hester Biosciences Analysis
Price Analysis
-
1 Week5.55%
-
3 Months47.15%
-
6 Month-23.03%
-
YTD-23.06%
-
1 Year-25.11%
Risk Meter
- 51% Low risk
- 51% Moderate risk
- 51% Balanced Risk
- 51% High risk
- 51% Extreme risk
Hester Biosciences News
Govt expects covid vaccines’ production capacity to increase from Dec
2 min read . 04 Aug 2021Hester Biosciences in talks with Bharat Biotech for production of Covaxin
2 min read . 16 May 2021Hester Biosciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 311.1
- Selling/ General/ Admin Expenses Total
- 62.42
- Depreciation/ Amortization
- 16.8
- Other Operating Expenses Total
- 99.3
- Total Operating Expense
- 266.85
- Operating Income
- 44.25
- Net Income Before Taxes
- 39.57
- Net Income
- 27.49
- Diluted Normalized EPS
- 33.89
- Period
- 2025
- Total Assets
- 653.39
- Total Liabilities
- 339.13
- Total Equity
- 314.26
- Tangible Book Valueper Share Common Eq
- 361.59
- Period
- 2025
- Cashfrom Operating Activities
- 64.51
- Cashfrom Investing Activities
- -19
- Cashfrom Financing Activities
- -51.72
- Net Changein Cash
- -6.72
- Period
- 2024
- Total Revenue
- 304.55
- Selling/ General/ Admin Expenses Total
- 124.91
- Depreciation/ Amortization
- 17.17
- Other Operating Expenses Total
- 3.17
- Total Operating Expense
- 266.28
- Operating Income
- 38.26
- Net Income Before Taxes
- 31.95
- Net Income
- 18.89
- Diluted Normalized EPS
- 21.27
- Period
- 2024
- Total Assets
- 662.35
- Total Liabilities
- 370.55
- Total Equity
- 291.79
- Tangible Book Valueper Share Common Eq
- 338.39
- Period
- 2024
- Cashfrom Operating Activities
- 48.13
- Cashfrom Investing Activities
- -22.65
- Cashfrom Financing Activities
- -26.04
- Net Changein Cash
- -0.41
- Period
- 2023
- Total Revenue
- 266.09
- Selling/ General/ Admin Expenses Total
- 116.18
- Depreciation/ Amortization
- 20.7
- Other Operating Expenses Total
- 3.74
- Total Operating Expense
- 236.18
- Operating Income
- 29.91
- Net Income Before Taxes
- 40.15
- Net Income
- 26.63
- Diluted Normalized EPS
- 31.29
- Period
- 2023
- Total Assets
- 669.97
- Total Liabilities
- 390.24
- Total Equity
- 279.73
- Tangible Book Valueper Share Common Eq
- 325.38
- Period
- 2023
- Cashfrom Operating Activities
- 23.6
- Cashfrom Investing Activities
- -77
- Cashfrom Financing Activities
- 41.76
- Net Changein Cash
- -11.59
- Period
- 2022
- Total Revenue
- 235.01
- Selling/ General/ Admin Expenses Total
- 95.9
- Depreciation/ Amortization
- 16.58
- Other Operating Expenses Total
- 2.72
- Total Operating Expense
- 191.6
- Operating Income
- 43.41
- Net Income Before Taxes
- 53.5
- Net Income
- 39.32
- Diluted Normalized EPS
- 46.11
- Period
- 2022
- Total Assets
- 562.16
- Total Liabilities
- 302.18
- Total Equity
- 259.98
- Tangible Book Valueper Share Common Eq
- 303.21
- Period
- 2022
- Cashfrom Operating Activities
- 8.81
- Cashfrom Investing Activities
- -116.59
- Cashfrom Financing Activities
- 111.61
- Net Changein Cash
- 3.48
- Period
- 2021
- Total Revenue
- 214.33
- Selling/ General/ Admin Expenses Total
- 80.37
- Depreciation/ Amortization
- 13.31
- Other Operating Expenses Total
- 4.92
- Total Operating Expense
- 158.98
- Operating Income
- 55.36
- Net Income Before Taxes
- 50.1
- Net Income
- 34.43
- Diluted Normalized EPS
- 43.16
- Period
- 2021
- Total Assets
- 411.05
- Total Liabilities
- 182.74
- Total Equity
- 228.31
- Tangible Book Valueper Share Common Eq
- 267.89
- Period
- 2021
- Cashfrom Operating Activities
- 58.05
- Cashfrom Investing Activities
- -38.37
- Cashfrom Financing Activities
- -18.22
- Net Changein Cash
- -2.26
- Period
- 2020
- Total Revenue
- 183.27
- Selling/ General/ Admin Expenses Total
- 76.68
- Depreciation/ Amortization
- 13.07
- Other Operating Expenses Total
- 3.92
- Total Operating Expense
- 140.61
- Operating Income
- 42.66
- Net Income Before Taxes
- 41.33
- Net Income
- 29.17
- Diluted Normalized EPS
- 33.89
- Period
- 2020
- Total Assets
- 386.6
- Total Liabilities
- 185.53
- Total Equity
- 201.07
- Tangible Book Valueper Share Common Eq
- 235.9
- Period
- 2020
- Cashfrom Operating Activities
- 38.29
- Cashfrom Investing Activities
- -74.47
- Cashfrom Financing Activities
- 18.62
- Net Changein Cash
- -17.56
- Period
- 2019
- Total Revenue
- 178.07
- Selling/ General/ Admin Expenses Total
- 56.77
- Depreciation/ Amortization
- 11.76
- Other Operating Expenses Total
- 1.84
- Total Operating Expense
- 121.6
- Operating Income
- 56.47
- Net Income Before Taxes
- 56.86
- Net Income
- 41.57
- Diluted Normalized EPS
- 48.93
- Period
- 2019
- Total Assets
- 299.45
- Total Liabilities
- 121.99
- Total Equity
- 177.46
- Tangible Book Valueper Share Common Eq
- 208.04
- Period
- 2019
- Cashfrom Operating Activities
- 47.4
- Cashfrom Investing Activities
- -21.73
- Cashfrom Financing Activities
- 2.65
- Net Changein Cash
- 28.32
- Period
- 2025-03-31
- Total Revenue
- 81.93
- Selling/ General/ Admin Expenses Total
- 14.19
- Depreciation/ Amortization
- 4.18
- Other Operating Expenses Total
- 27.81
- Total Operating Expense
- 66.92
- Operating Income
- 15.01
- Net Income Before Taxes
- 3.75
- Net Income
- 1.29
- Diluted Normalized EPS
- 1.82
- Period
- 2025-03-31
- Total Assets
- 653.39
- Total Liabilities
- 339.13
- Total Equity
- 314.26
- Tangible Book Valueper Share Common Eq
- 361.59
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 64.51
- Cashfrom Investing Activities
- -19
- Cashfrom Financing Activities
- -51.72
- Net Changein Cash
- -6.72
- Period
- 2024-12-31
- Total Revenue
- 63.22
- Selling/ General/ Admin Expenses Total
- 16.34
- Depreciation/ Amortization
- 4.29
- Other Operating Expenses Total
- 22.19
- Total Operating Expense
- 62.45
- Operating Income
- 0.77
- Net Income Before Taxes
- 13.37
- Net Income
- 11.66
- Diluted Normalized EPS
- 13.41
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 83.69
- Selling/ General/ Admin Expenses Total
- 15.9
- Depreciation/ Amortization
- 4.2
- Other Operating Expenses Total
- 24.12
- Total Operating Expense
- 68.73
- Operating Income
- 14.96
- Net Income Before Taxes
- 11.87
- Net Income
- 8.2
- Diluted Normalized EPS
- 9.86
- Period
- 2024-09-30
- Total Assets
- 669.25
- Total Liabilities
- 367.42
- Total Equity
- 301.83
- Tangible Book Valueper Share Common Eq
- 350.11
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 24.12
- Cashfrom Investing Activities
- -12.97
- Cashfrom Financing Activities
- -10.14
- Net Changein Cash
- 0.82
- Period
- 2024-06-30
- Total Revenue
- 82.27
- Selling/ General/ Admin Expenses Total
- 16
- Depreciation/ Amortization
- 4.13
- Other Operating Expenses Total
- 25.18
- Total Operating Expense
- 68.75
- Operating Income
- 13.52
- Net Income Before Taxes
- 10.59
- Net Income
- 6.34
- Diluted Normalized EPS
- 8.8
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 79.26
- Selling/ General/ Admin Expenses Total
- 16.1
- Depreciation/ Amortization
- 3.74
- Other Operating Expenses Total
- 25.69
- Total Operating Expense
- 67.08
- Operating Income
- 12.18
- Net Income Before Taxes
- 9.87
- Net Income
- 4.95
- Diluted Normalized EPS
- 4.98
- Period
- 2024-03-31
- Total Assets
- 662.35
- Total Liabilities
- 370.55
- Total Equity
- 291.79
- Tangible Book Valueper Share Common Eq
- 338.39
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 48.13
- Cashfrom Investing Activities
- -22.65
- Cashfrom Financing Activities
- -26.04
- Net Changein Cash
- -0.41
- Period
- 2023-12-31
- Total Revenue
- 66.98
- Selling/ General/ Admin Expenses Total
- 15.58
- Depreciation/ Amortization
- 3.75
- Other Operating Expenses Total
- 20.61
- Total Operating Expense
- 60.58
- Operating Income
- 6.41
- Net Income Before Taxes
- 6.41
- Net Income
- 3.98
- Diluted Normalized EPS
- 4.73
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Hester Biosciences Technical
Moving Average
SMA
- 5 Day1790.17
- 10 Day1814.1
- 20 Day1822.55
- 50 Day1805.45
- 100 Day1708.71
- 300 Day2058.35
Hester Biosciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Bajaj Healthcare
- 518.9
- -4.4
- -0.84
- 744.9
- 312.7
- 1640.73
- Bliss Gvs Pharma
- 157.05
- 8.25
- 5.54
- 184.95
- 101
- 1652.62
- Hester Biosciences
- 1868
- 51.25
- 2.82
- 3375.45
- 1246.75
- 1589.69
- Lincoln Pharmaceuticals
- 567.45
- 6.45
- 1.15
- 975
- 500
- 1134.57
- Kwality Pharmaceuticals
- 1014.55
- -10.35
- -1.01
- 1140
- 481
- 1054.68
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Bajaj Healthcare
- 36.71
- 3.55
- 16
- 8.22
- Bliss Gvs Pharma
- 18.72
- 1.49
- 7.19
- 9.45
- Hester Biosciences
- 53.74
- 4.93
- 11.14
- 11.44
- Lincoln Pharmaceuticals
- 13.7
- 1.68
- 15.87
- 14.56
- Kwality Pharmaceuticals
- 26.72
- 4.03
- 26.54
- 13.21
Hester Biosciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-May-25
- Audited Results & Final Dividend
- 30-Jan-25
- Quarterly Results
- 28-Oct-24
- Quarterly Results
- 02-Aug-24
- Quarterly Results
- 10-May-24
- Audited Results & Dividend
- 02-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 08-Aug-23
- Quarterly Results
- 17-May-23
- Audited Results & Final Dividend
- 31-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 15-Feb-25
- 13-Jan-25
- POM
- 29-Aug-24
- 26-Jul-24
- AGM
- 20-Sept-23
- 23-Aug-23
- AGM
- 02-May-23
- 28-Mar-23
- POM
- 17-Aug-21
- 23-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-May-25
- -
- -
- 7
- 10-May-24
- -
- 22-Aug-24
- 6
- 17-May-23
- -
- 13-Sept-23
- 8
- 08-Jun-21
- -
- 05-Aug-21
- 10


